Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Bone Biologics expects completion of patient recruitment for NB1 study by end of 2025
Bone Biologics says it expects to complete recruitment for the first-in-human NB1 study in degenerative disc disease in Australia by the end of 2025. The multicenter study of up to 30 patients compares two NB1 concentrations with autograft; NB1 combines NELL-1 with demineralized bone matrix. The company has extended product shelf life from 12 to 18 months, is targeting 24 months, and plans additional clinical sites, an improved potency assay and an interim report after all patients reach the six-month follow-up. Bone Biologics completed a $5m capital raise at the end of June, which is expected to fund operations into Q2 2026; a 1:6 reverse stock split also took effect in June. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 896,15 Mio | 13.780,59% |
| Utile lordo | 352,39 Mio | 11,13% |
| Utile netto | 7,04 Mio | 87,40% |
| EBITDA | 45,01 Mio | 16,36% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 3,45 Mrd€ |
Numero di azioni | 329,42 Mio |
Massimo/minimo a 52 settimane | 12,88€ - 8,63€ |
| Dividendi | No |
Beta | 0,14 |
Rapporto P/E | −6,79 |
Rapporto PEG | 0,01 |
Rapporto P/B | 1,08 |
Rapporto P/S | 0,94 |
Profilo aziendale
Bone Therapeutics SA ist ein Biotechnologieunternehmen, das sich mit der Entwicklung von Zelltherapieprodukten für die Orthopädie und Knochenerkrankungen befasst. Zu den Produkten des Unternehmens gehören ALLOB, ein allogenes Zelltherapieprodukt, das sich in der klinischen Phase I/IIa zur Behandlung von Frakturen mit verzögerter Knochenheilung und von Lendenwirbelfusionen befindet, sowie JTA-004, ein intraartikuläres Injektionsmittel, das sich in der klinischen Phase III zur Behandlung von osteoarthritischen Schmerzen im Knie befindet. Bone Therapeutics SA wurde im Jahr 2006 gegründet und hat seinen Sitz in Mont-Saint-Guibert, Belgien.
| Nome | Bone Therapeutics |
| CEO | Yasuhiro Ohmura |
| Sede centrale | Tokyo,
ty Belgio |
| Sito web | |
| Quotazione in borsa | 06/02/2015 |
| Dipendenti | 19.928 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | BOTHE.BR |
Brussels Stock Exchange | BOTHE.BR |
Düsseldorf | BT1.DU |
Frankfurt | BT1.F |
London | 0R55.L |
London Stock Exchange | 0R55.L |
Pnk | NINOY |
Toronto Stock Exchange | TOH.V |
Scopri gli asset
Gli azionisti di Bone Therapeutics investono anche nei seguenti asset
